Purpose of ReviewAlthough statin therapy is well established to prevent atherosclerotic vascular disease (ASCVD) events in adults 40 to 75 years of age, it is less clear whether older adults benefit from statin therapy. The purpose of this review is to summarize the current evidence and guidelines on statin use for primary and secondary prevention in older patients.Recent FindingsModerate to high intensity statin therapy decreases cardiovascular event rates in older patients with or at risk for ASCVD. Cardiac biomarkers and coronary calcium scoring can identify older patients at higher ASCVD risk who may benefit from statin therapy.SummaryAge alone should not be a deterrent to statin therapy in older patients. The decision to initiate statin therapy should occur after a patient to clinician discussion based on the patient's overall ASCVD risk and weighed against other clinical factors that influence the patient's life expectancy and quality of life.
Journal article
Statin Therapy for Primary and Secondary Prevention in Older Adults
Current atherosclerosis reports, v 27(1), p11
2024
PMID: 39585440
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Metrics
Details
- Title
- Statin Therapy for Primary and Secondary Prevention in Older Adults
- Creators
- Alicia Bao - Thomas Jefferson University HospitalDean G. Karalis - Thomas Jefferson University Hospital
- Publication Details
- Current atherosclerosis reports, v 27(1), p11
- Publisher
- Springer US; PHILADELPHIA
- Number of pages
- 8
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001362550700002
- Scopus ID
- 2-s2.0-85210086645
- Other Identifier
- 991021963515204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Peripheral Vascular Disease